Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

ProfoundBio Cleared to Start US Trials of ADC for Solid Tumor Cancers

publication date: Aug 4, 2022

ProfoundBio, a Suzhou-Seattle oncology biopharma, was approved to start US trials of an antibody drug candidate in patients with advanced cancers. PRO1184 consists of a folate receptor alpha (FRa) directed antibody conjugated to an exatecan payload with a novel hydrophilic linker. The Phase 1 trial will evaluate the safety, activity and pharmacokinetics of PRO1184 in patients with ovarian, endometrial, breast, non-small cell lung cancers and mesothelioma. ProfoundBio develops novel antibody therapeutics aimed at solid tumor cancers. In 2021, Profound was formed with $58 million in capital from China investors and leadership from SeaGen veterans. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
November 8-11, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022